Erythropoiesis stimulating agents (ESAs), the active ingredients of whichare recombinant human erythropoietin or its modified form, have been widely used to treat patients with certain kinds of anemia, for example chronic kidney disease-associated anemia, in clinical practice [1]. This evidence concerns the gene EPO and anemia.